BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 19204419)

  • 1. Assessing patient readiness for the clinical adoption of personalized medicine.
    Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
    Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine.
    Jain KK
    Curr Opin Mol Ther; 2002 Dec; 4(6):548-58. PubMed ID: 12596356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current status and future potential of personalized diagnostics: Streamlining a customized process.
    Richmond TD
    Biotechnol Annu Rev; 2008; 14():411-22. PubMed ID: 18606372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine: elusive dream or imminent reality?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Jun; 81(6):807-16. PubMed ID: 17505496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
    Walk EE
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Getting to personalized cancer medicine: taking out the garbage.
    Compton C
    Cancer; 2007 Oct; 110(8):1641-3. PubMed ID: 17763370
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular diagnostics and personalized medicine. IBC Life Sciences Conference on Pharmacogenomics, June 24-25, 2003, London, UK.
    Sanders R
    Pharmacogenomics; 2003 Sep; 4(5):541-5. PubMed ID: 14518454
    [No Abstract]   [Full Text] [Related]  

  • 9. The disruptive nature of personalized medicine technologies: implications for the health care system.
    Carlson RJ
    Public Health Genomics; 2009; 12(3):180-4. PubMed ID: 19204421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.
    Issa AM
    Adv Health Econ Health Serv Res; 2008; 19():191-206. PubMed ID: 19548519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs.
    Phillips KA; Veenstra DL; Ramsey SD; Van Bebber SL; Sakowski J
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):425-32. PubMed ID: 15298364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics: the promise of personalized medicine.
    Hood E
    Environ Health Perspect; 2003 Aug; 111(11):A581-9. PubMed ID: 12928155
    [No Abstract]   [Full Text] [Related]  

  • 13. Personalized medicine: challenges in assessing and capturing value in the commercial environment.
    Ferrara J
    Expert Rev Mol Diagn; 2006 Mar; 6(2):129-31. PubMed ID: 16512770
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacogenomics, personalized medicine, and heart failure.
    Mestroni L; Taylor MR
    Discov Med; 2011 Jun; 11(61):551-61. PubMed ID: 21712021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Provision of personalized genomic diagnostic technologies for breast and colorectal cancer: an analysis of patient needs, expectations and priorities.
    Issa AM; Hutchinson JF; Tufail W; Fletcher E; Ajike R; Tenorio J
    Per Med; 2011 Jul; 8(4):401-411. PubMed ID: 29783336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman R
    Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine prompts push to redesign clinical trials.
    Singer E
    Nat Med; 2005 May; 11(5):462. PubMed ID: 15875041
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing.
    Cuffe S; Hon H; Qiu X; Tobros K; Wong CK; De Souza B; McFarlane G; Masroor S; Azad AK; Hasani E; Rozanec N; Leighl N; Alibhai S; Xu W; Issa AM; Liu G
    Pharmacogenet Genomics; 2014 Jul; 24(7):348-55. PubMed ID: 24911662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the value of electronic prescribing in ambulatory care: a focus group study.
    Weingart SN; Massagli M; Cyrulik A; Isaac T; Morway L; Sands DZ; Weissman JS
    Int J Med Inform; 2009 Sep; 78(9):571-8. PubMed ID: 19395307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure and personalized medicine.
    Mestroni L; Merlo M; Taylor MR; Camerini F; Sinagra G
    J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):6-12. PubMed ID: 20814312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.